Tag: FDA Fast Track Designation
Bryn Pharma Completes Dosing in Pivotal Clinical Trial Designed to Support...
Nasal Spray Product is Disruptive Innovation for People at Risk of Anaphylaxis.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray
Company provides a novel means of administering emergency epinephrine.
FDA Grants Fast Track Designation for Epinephrine Nasal Spray as Investigational...
"A significant milestone for INSYS and our clinical development of this novel drug-device combination.”
